Mode
Text Size
Log in / Sign up
Phase 3 N=478 Randomized Treatment

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Prostate Cancer

Enrolled (actual)
478
Serious AEs
Results posted
Mar 2019
Primary outcome: Primary: Time to Progression — 683.0; 549.0 days — p=0.76

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
dietary education and counseling (Other); prostate cancer foundation booklet (Other)
Age
Adult, Older Adult · 50+ yrs
Sex
Male
Sponsor
Alliance for Clinical Trials in Oncology
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Progression
683.0; 549.0 0.76
SECONDARY
Time to Treatment: Censoring Death, Progression or Last Follow-up as Measured by Number of Events Observed
3; 2 0.71
SECONDARY
Quality of Life (QOL) Was Measured Using Change From Baseline in Total Summary Score of Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at Month 24
2.0; 2.8 0.995
SECONDARY
Total Vegetables (Servings Per Day) Evaluated at Baseline and Month 24 Based on Dietary Recall
2.01; 0.37 <0.001 sig

Summary

RATIONALE: Eating a diet high in vegetables may slow down disease progression in patients with prostate cancer. PURPOSE: This randomized clinical trial is studying how well diet works in altering disease progression in patients with prostate cancer on active surveillance.

Eligibility Criteria

Preregistration Eligibility:

  • Histologic Documentation:
  • The initial biopsy showing diagnosis of prostate cancer should be used for the purposes of determining eligibility.
  • However, if a subsequent biopsy performed before patient enrollment shows that the patient is ineligible, he may not be enrolled to the study.
  • Eligible patients must meet all of the following criteria:
  • Biopsy-proven (consisting of ≥ 10 tissue cores) adenocarcinoma of the prostate diagnosed within 24 months prior to pre-registration
  • 70 years, biopsy Gleason score ≤ (3 + 4) = 7.
  • Required Initial Laboratory Values:
  • Serum PSA < 10 ng/mL
  • NOTE: Baseline PSA for determination of eligibility must be measured after discontinuation of any 5-alpha reductase inhibitors.

Registration Eligibility:

  • Successful completion of three 24-hour dietary recalls during the run-in period.
  • Patients consuming ≥ 6 servings per day of fruits and vegetables (not including juices), as determined by the run-in dietary recalls are not eligible.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01238172). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search